CLINICAL TRIALS PROFILE FOR FERRLECIT
✉ Email this page to a colleague
All Clinical Trials for FERRLECIT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00223938 ↗ | Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients. | Terminated | Sanofi | Phase 4 | 2003-12-30 | This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin. |
NCT00223938 ↗ | Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients. | Terminated | Watson Pharmaceuticals | Phase 4 | 2003-12-30 | This is a phase 4 clinical investigation of the efficacy and safety of Ferrlecit in the maintenance of iron stores and serum hemoglobin concentration in hemodialysis patients receiving Erythropoietin. |
NCT00223964 ↗ | Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients | Completed | Watson Pharmaceuticals | Phase 4 | 2003-06-01 | This was a multi-center study in iron-deficient pediatric hemodialysis patients, whose legal guardian had provided signed informed consent and satisfied the inclusion and exclusion criteria. |
NCT00223977 ↗ | 2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients. | Completed | Watson Pharmaceuticals | Phase 2/Phase 3 | 2003-12-01 | This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio. |
NCT00224003 ↗ | Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients | Completed | Watson Pharmaceuticals | Phase 4 | 2003-04-01 | A phase 4 clinical investigation in iron-replete pediatric hemodialysis patients, whose legal guardian had provided signed informed consent, and who had satisfied the inclusion and exclusion criteria of the study. |
NCT00224042 ↗ | Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents | Completed | Watson Pharmaceuticals | Phase 4 | 2003-04-01 | This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents, such as Procrit® and Aranesp®. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FERRLECIT
Condition Name
Clinical Trial Locations for FERRLECIT
Trials by Country
Clinical Trial Progress for FERRLECIT
Clinical Trial Phase
Clinical Trial Sponsors for FERRLECIT
Sponsor Name